Create an Account

Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Chapter 1: Chapter 1: Introduction + Clinical Advances in BCMA-directed Bispecific Antibody Therapy

8 chapters
Play All
ReachMD Healthcare Image
Media formats available:
Details
Program chapters
Presenters
Related
Comments

  • Overview

    This activity is not accredited for CME/CE credit.

    This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

  • Provider(s)/Educational Partner(s)

    Jointly provided by:

  • Commercial Support

    Support for this activity has been provided through educational grants from Johnson & Johnson and Pfizer, Inc.

  • Target Audience

    This activity has been designed to meet the educational needs of community hematologist-oncologists and other health care providers involved in the care of RRMM patients.

  • Learning Objectives

    After completing this activity, participants should be better able to:

    • Evaluate recent clinical advances in the use of bispecific antibody therapy in patients with RRMM and their implications for clinical practice
    • Summarize the toxicity profiles of bispecific antibodies used in the treatment of RRMM, particularly with respect to CRS, neurotoxicity, and infections
    • Employ the recommended strategies to monitor for treatment complications and manage AEs associated with bispecific antibody therapy

  • Unapproved Product Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, and Pfizer do not recommend the use of any agent outside the labeled indications.

  • Disclaimer

    The information presented in this activity is for medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Contact Information

  • Privacy

    This content is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.

  • Copyright

    © 2024. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.

Presenters

Related

  • Concensus Recommendations for Management of Infections in Patients Receiving Bispecific Antibody Therapy

    Concensus Recommendations for Management of Infections in Patients Receiving Bispecific Antibody Therapy

    Show more
  • Bispecific Antibody Discussion Handout

    Bispecific Antibody Discussion Handout

    Show more
  • Common Terminology Criteria for Adverse Events (CTCAE)

    Common Terminology Criteria for Adverse Events (CTCAE)

    Show more

Facebook Comments

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

    Welcome to the new
    Global Oncology Academy website.

    NEW FEATURES:

    • Check out all the new educational programs we have added.New educational programs
    • Now mobile-friendly and easier to navigate.Now mobile-friendly
    • A learner profile that stores your history/CME certificates.Track your credits
    Register

    We’re glad to see you’re enjoying Global Oncology Academy…
    but how about a more personalized experience?

    Register for free
    You are now leaving Global Oncology Academy and going to a site run by another organization.

    Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.